Recent Transactions

20-Feb-24
Pending
$185 million
Australia flag
Target: 

myHomecare Group

Australia flag
Acquiror: 
Australian Unity

Advising Australian Unity on its acquisition of myHomecare Group

30-Dec-22
$153 million
United States flag
Target: 

Annovera®, Imvexxy®, Bijuva®, and prescription prenatal vitamin products

Australia flag
Acquiror: 
Mayne Pharma

Advised TherapeuticsMD, Inc., an innovative, leading women’s healthcare company on definitive agreements to license its products to Mayne Pharma

24-Nov-22
Pending
Undisclosed
Target: 

Kyowa Kirin International’s established medicines business

Germany flag
Acquiror: 
Grünenthal

Advising Kyowa Kirin International, a subsidiary of Kyowa Kirin Co., Ltd, a Japanese global specialty pharma company, on a collaboration agreement with Grünenthal GmbH, a global, science-based, privately-owned pharmaceutical company

07-Dec-21
$153 million
Japan flag
Target: 

Japan Medical Dynamic Marketing

Japan flag
Acquiror: 
Mitsui Chemicals

Advising Mitsui Chemicals,  one of the largest Japanese chemical companies, on the acquisition of a 30% stake in Japan Medical Dynamic Marketing, a leading orthopedic medical device manufacturer in Japan, held by NGK SPARK PLUG

30-Jun-21
Pending
Undisclosed
Spain flag
Target: 

Deltalab

Thailand flag
Acquiror: 
SCG Packaging Public Company Limited

Advising Deltalab, a leading Spanish laboratory solutions provider with dedicated manufacturing capacity, on the sale of the company to SCG Packaging Public Company Limited, the largest integrated packaging and paper company in Southeast Asia

10-Jun-20
$134 million
Saudi Arabia Flag
Target: 

Equity stake in Bupa Arabia

United Kingdom flag
Acquiror: 
Bupa Ltd.

Advising Bupa, a leading international healthcare group, on the increase of its stake in Bupa Arabia,  the largest health insurance provider in the Kingdom of Saudi Arabia

20-Feb-20
$NA
United Kingdom flag
Target: 

Asia and US rights to Physiogel

Korea flag
Acquiror: 
LG Household & Health Care

Advised GlaxoSmithKline plc (“GSK”), the UK listed international pharmaceutical and consumer healthcare company, on the divestiture of the rights to Physiogel Asia and the US to Korea-based LG Household & Health Care Ltd

19-Dec-18
$NA
Australia flag
Target: 

Starpharma Holdings Limited, patented VivaGel BV® product

Italy, USA flags
Acquiror: 
ITF Pharma, US subsidiary of Italfarmaco S.p.A.

Advised Starpharma Holdings Limited on a US licensing agreement of its patented VivaGel BV® product with ITF Pharma, a US subsidiary of Italfarmaco S.p.A., a privately held European specialty pharmaceutical company

03-Dec-18
$4.0 billion
United Kingdom flag
Target: 

Assets owned by GlaxoSmithKline plc

Acquiror: 
Unilever plc / Hindustan Unilever Limited

Advised GlaxoSmithKline plc, the UK listed international pharmaceutical and consumer healthcare company, on the divestment of Horlicks and other consumer healthcare nutrition brands to Unilever plc, and on the merger of GSK Consumer Healthcare Limited with Hindustan Unilever Limited

10-Sep-18
$100 million
Australia flag
Target: 

Montserrat Day Hospital Group

Australia flag
Acquiror: 
Primary Health Care

Advised ASX-listed Primary Health Care, one of Australia’s leading providers of multi-disciplinary healthcare services, on its acquisition of the Montserrat Day Hospital Group, an owner and operator of day hospital facilities

30-Nov-17
$NA
Germany flag
Target: 

MorphoSys AG

China flag
Acquiror: 
I-Mab

Advised MorphoSys AG, a German biopharmaceutical company, on a regional licensing agreement covering Greater China and comprising its investigational anti-CD38 antibody MOR202 targeting multiple myeloma, with I-Mab

05-Oct-16
$775 million
U.K., Ireland flags
Target: 

Assets and operations of Actavis Generics in the UK and Ireland from Teva Pharmaceutical Industries Ltd.

India flag
Acquiror: 
Accord Healthcare Ltd.

Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on its sale of assets and operations of Actavis Generics in the UK and Ireland to Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Limited) for £603m (c.$775m) 

05-Oct-16
$NA
Israel flag
Target: 

Portfolio of 14 Outlicensing generic products in the EEA from Teva Pharmaceutical Industries Ltd.

India flag
Acquiror: 
Accord Healthcare Ltd.

Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on the divestment of a portfolio of 14 Outlicensing pharmaceutical products in the EEA to Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Limited).

28-Jun-16
$652 million
Israel flag
Target: 

US rights to 37 approved and 5 pipeline generic products

Australia flag
Acquiror: 
Mayne Pharma Group Limited

Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 42 generic products

20-Jun-16
$NA
Israel flag
Target: 

US rights to 2 generic drug products from Teva Pharmaceutical Industries Ltd.

India flag
Acquiror: 
Zydus Cadila

Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 2 generic drug products to Zydus Cadila

11-Jun-16
$350 million
Israel flag
Target: 

US rights to 8 generic drug products from Teva Pharmaceutical Industries Ltd.

India flag
Acquiror: 
Dr. Reddy’s Laboratories

Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 8 generic drug products to Dr. Reddy’s Laboratories

27-Jul-15
$40.5 billion
Ireland flag
Target: 

Allergan Generics

Israel flag
Acquiror: 
Teva Pharmaceutical Industries Ltd.

Advised Teva Pharmaceutical Industries Ltd., a leading global pharmaceutical company, on the acquisition of Allergan plc’s Generics business

28-Jul-14
$90 million
Australia flag
Target: 

Clinuvel Pharmaceuticals Limited

United States flag
Acquiror: 
Retrophin, Inc.

Advised Clinuvel, a biopharmaceutical company focused on developing drugs for the treatment of a range of severe skin disorders, in response to an unsolicited proposal to acquire the business from Retrophin, a pharmaceutical company focused on the development, acquisition and commercialization of drugs for the treatment of serious, catastrophic or rare diseases

21-Nov-11
$689 million
Australia flag
Target: 

iNova Pharmaceuticals

United States flag
Acquiror: 
Valeant Pharmaceuticals

Advised Archer Capital and Ironbridge Capital on the sale of iNova Pharmaceuticals, a leading pharmaceuticals company that sells and distributes a range of prescription and over-the-counter products in Australia, New Zealand, Asia and Southern Africa, to Valeant Pharmaceuticals

26-Nov-10
$118 million
Australia flag
Target: 

Healthcare Australia

United Kingdom flag
Acquiror: 
Healthcare Locums

Advised CHAMP Private Equity on the sale of Healthcare Australia, a leading provider of nursing agency staff to public and private health institutions in Australia, to Healthcare Locums, a healthcare recruitment agency based in the UK

21-Sep-10
$234 million
Israel flag
Target: 

Taro Pharmaceutical Industries

India flag
Acquiror: 
Sun Pharmaceutical Industries Ltd.

Advised Sun Pharmaceutical Industries Ltd., the largest Indian pharmaceutical company by market capitalization, on its acquisition of a majority interest in Israeli based Taro Pharmaceutical Industries, a multinational generics pharmaceutical company

show all